Related Experiment Videos
Brotizolam and chronic insomnia: a multi-centre study.
British Journal of Clinical Pharmacology
|January 1, 1983
Summary
Brotizolam effectively treats chronic insomnia by reducing sleep onset and nocturnal awakenings. This study found no dose-related side effects or rebound insomnia upon withdrawal, indicating good tolerability.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Trials
Background:
- Chronic insomnia significantly impacts quality of life.
- Effective and safe treatment options for insomnia are needed.
Purpose of the Study:
- To evaluate the acceptability and efficacy of brotizolam at different doses.
- To assess potential side effects and rebound insomnia.
Main Methods:
- Double-blind, crossover study design.
- Inclusion of 75 chronic insomniacs (33 male, 42 female) aged 21-75.
- Administration of brotizolam at 0.125, 0.25, and 0.5 mg doses.
Main Results:
- Patients experienced reduced sleep latency and fewer nocturnal awakenings.
- Sleep improvement was noted within the first week at 0.25 mg.
- No dose-dependent adverse events were reported.
Conclusions:
- Brotizolam is an acceptable treatment for chronic insomnia.
- The medication demonstrates efficacy without significant side effects or rebound insomnia.
- Further research may explore long-term safety and efficacy profiles.